Search

Displaying results 4751 - 4760 of 10000 in total
  1. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  2. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  3. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.

    Synonyms: n-6 fatty acids
  4. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  5. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. … Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.

  6. Drug

    Cystic fibrosis transmembrane conductance regulator

    go.drugbank.com/drugs/DB15180
    Investigational

    Cystic fibrosis transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis).

    Categories: Ion Pumps, Ion Channels
  7. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  8. Drug

    Rocaglamide

    go.drugbank.com/drugs/DB15495
    Experimental

    [didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of … [A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_.

  9. Drug

    Elinogrel

    go.drugbank.com/drugs/DB06350
    Investigational

    A P2Y12 inhibitor and platelet aggregation inhibitor.

  10. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections. … PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small

    Synonyms: PEG INF alfacon-1